Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Unknown 1Terminated 1No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Melanoma 2Breast Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Rose Bengal × Clear all
NCT00521053 2014-08-25

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Provectus Pharmaceuticals

Phase 2 Completed
80 enrolled 14 charts
Dermatologic

Melanoma

NCT00237354 2008-10-24

PV-10 Chemoablation of Recurrent Breast Carcinoma

Provectus Pharmaceuticals

Phase 1 Completed
15 enrolled
Breast

Breast Neoplasms

NCT00219843 2007-08-23

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Provectus Pharmaceuticals

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡